All Title Author
Keywords Abstract

Cholesterol  2013 

Current Views on Genetics and Epigenetics of Cholesterol Gallstone Disease

DOI: 10.1155/2013/298421

Full-Text   Cite this paper   Add to My Lib

Abstract:

Cholesterol gallstone disease, one of the commonest digestive diseases in western countries, is induced by an imbalance in cholesterol metabolism, which involves intestinal absorption, hepatic biosynthesis, and biliary output of cholesterol, and its conversion to bile acids. Several components of the metabolic syndrome (e.g., obesity, type 2 diabetes, dyslipidemia, and hyperinsulinemia) are also well-known risk factors for gallstones, suggesting the existence of interplay between common pathophysiological pathways influenced by insulin resistance, genetic, epigenetic, and environmental factors. Cholesterol gallstones may be enhanced, at least in part, by the abnormal expression of a set of the genes that affect cholesterol homeostasis and lead to insulin resistance. Additionally, epigenetic mechanisms (mainly DNA methylation, histone acetylation/deacetylation, and noncoding microRNAs) may modify gene expression in the absence of an altered DNA sequence, in response to different lithogenic environmental stimuli, such as diet, lifestyle, pollutants, also occurring in utero before birth. In this review, we will comment on various steps of the pathogenesis of cholesterol gallstones and interaction between environmental and genetic factors. The epigenomic approach may offer new options for therapy of gallstones and better possibilities for primary prevention in subjects at risk. 1. Introduction Cholesterol gallstone disease is one of the most prevalent and most costly digestive diseases requiring hospital admission, since its prevalence ranges from 10% to 15% in adults. Medical expenses for gallstone treatment exceeded $4 billion in facility charges in 2004 in the United States [1] and rise to $6.5 billion when surgical complications occur [2]. The formation and growth of cholesterol gallstones, which accounts for 75% of the gallstones in westernized countries [3–5], are secondary to abnormal cholesterol homeostasis [6]. Of note, the main risk factors for cholesterol gallstone disease (e.g., obesity, type 2 diabetes, dyslipidemia, and hyperinsulinemia) are also well-known components of the metabolic syndrome [7–11], supporting the hypothesis that gallstone disease is just another component of the metabolic syndrome [12–14] (Table 1). Due to the high prevalence of the metabolic syndrome, it has been suggested that the phenotype of cholesterol gallstones may result from the interaction between insulin resistance, genetic factors, and a number of environmental factors [15]. A series of gallstone (LITH) genes have been identified, which affect cholesterol

References

[1]  J. E. Everhart and C. E. Ruhl, “Burden of digestive diseases in the united states part I: overall and upper gastrointestinal diseases,” Gastroenterology, vol. 136, no. 2, pp. 376–386, 2009.
[2]  E. A. Shaffer, “Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21st century?” Current Gastroenterology Reports, vol. 7, no. 2, pp. 132–140, 2005.
[3]  A. F. Attili, R. Capocaccia, N. Carulli et al., “Factors associated with gallstone disease in the MICOL experience,” Hepatology, vol. 26, no. 4, pp. 809–818, 1997.
[4]  A. F. Attili, N. Carulli, E. Roda et al., “Epidemiology of gallstone disease in Italy: prevalence data of the multicenter Italian study on cholelithiasis (M.I.COL.),” The American Journal of Epidemiology, vol. 141, no. 2, pp. 158–165, 1995.
[5]  A. K. Diehl, “Epidemiology and natural history of gallstone disease,” Gastroenterology Clinics of North America, vol. 20, no. 1, pp. 1–19, 1991.
[6]  P. Portincasa and D. Q. Wang, “Intestinal absorption, hepatic synthesis, and biliary secretion of cholesterol: where are we for cholesterol gallstone formation?” Hepatology, vol. 55, no. 5, pp. 1313–1316, 2012.
[7]  R. H. Eckel, S. M. Grundy, and P. Z. Zimmet, “The metabolic syndrome,” The Lancet, vol. 365, no. 9468, pp. 1415–1428, 2005.
[8]  S. M. Grundy, “Metabolic syndrome scientific statement by the American heart association and the national heart, lung, and blood institute,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 11, pp. 2243–2244, 2005.
[9]  S. M. Grundy and J. P. Barnett, “Metabolic and health complications of obesity,” Disease-a-Month, vol. 36, no. 12, pp. 641–731, 1990.
[10]  S. M. Grundy, J. I. Cleeman, S. R. Daniels et al., “Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement,” Circulation, vol. 112, no. 17, pp. 2735–2752, 2005.
[11]  C. J. Tsai, M. F. Leitzmann, W. C. Willett, and E. L. Giovannucci, “Prospective study of abdominal adiposity and gallstone disease in US men,” The American Journal of Clinical Nutrition, vol. 80, no. 1, pp. 38–44, 2004.
[12]  N. Méndez-Sánchez, N. C. Chavez-Tapia, D. Motola-Kuba et al., “Metabolic syndrome as a risk factor for gallstone disease,” World Journal of Gastroenterology, vol. 11, no. 11, pp. 1653–1657, 2005.
[13]  F. Nervi, J. F. Miquel, M. Alvarez et al., “Gallbladder disease is associated with insulin resistance in a high risk Hispanic population,” Journal of Hepatology, vol. 45, no. 2, pp. 299–305, 2006.
[14]  N. Ata, M. Kucukazman, B. Yavuz et al., “The metabolic syndrome is associated with complicated gallstone disease,” Canadian Journal of Gastroenterology, vol. 25, no. 5, pp. 274–276, 2011.
[15]  D. Q. Wang, D. E. Cohen, and M. C. Carey, “Biliary lipids and cholesterol gallstone disease,” Journal of Lipid Research, vol. 50, supplement, pp. S406–S411, 2009.
[16]  E. A. Mazzio and K. F. Soliman, “Basic concepts of epigenetics: impact of environmental signals on gene expression,” Epigenetics, vol. 7, no. 2, pp. 119–130, 2012.
[17]  P. Portincasa, A. Moschetta, and G. Palasciano, “Cholesterol gallstone disease,” The Lancet, vol. 368, no. 9531, pp. 230–239, 2006.
[18]  A. F. Hofmann, A. Amelsberg, and E. Vansonnenberg, “Pathogenesis and treatment of gallstones,” The New England Journal of Medicine, vol. 328, 25, pp. 1854–1855, 1993.
[19]  J. T. Lamont and M. C. Carey, “Cholesterol gallstone formation. 2. Pathobiology and pathomechanics,” Progress in liver diseases, vol. 10, pp. 165–191, 1992.
[20]  P. Portincasa, A. Di Ciaula, G. Baldassarre et al., “Gallbladder motel function in gallstone patients: sonographic and in vitro studies on the role of gallstones; smooth muscle function and gallbladder wall inflammation,” Journal of Hepatology, vol. 21, no. 3, pp. 430–440, 1994.
[21]  D. Q. Wang, B. A. Neuschwander-Tetri, and P. Portincasa, The Biliary System, Morgan & Claypool Life Sciences, Princeton, NJ, USA, 2012.
[22]  F. Lammert and J. F. Miquel, “Gallstone disease: from genes to evidence-based therapy,” Journal of Hepatology, vol. 48, supplement 1, pp. S124–S135, 2008.
[23]  F. Lammert and T. Sauerbruch, “Mechanisms of disease: the genetic epidemiology of gallbladder stones,” Nature Clinical Practice Gastroenterology and Hepatology, vol. 2, no. 9, pp. 423–433, 2005.
[24]  P. Portincasa, A. Di Ciaula, H. H. Wang et al., “Coordinate regulation of gallbladder motor function in the gut-liver axis,” Hepatology, vol. 47, no. 6, pp. 2112–2126, 2008.
[25]  P. Portincasa, A. Moschetta, F. Puglisi, and D. Q. H. Wang, “Medical treatment of gallstone disease,” in Biliary Lithiasis: Basic Science, Current Diagnosis and Management, G. Borzellino and C. Cordiano, Eds., pp. 149–157, Springer Italia S.r.l., Milan, Italy, 2008.
[26]  D. Q. H. Wang, L. Zhang, and H. H. Wang, “High cholesterol absorption efficiency and rapid biliary secretion of chylomicron remnant cholesterol enhance cholelithogenesis in gallstone-susceptible mice,” Biochimica et Biophysica Acta, vol. 1733, no. 1, pp. 90–99, 2005.
[27]  H. H. Wang, P. Portincasa, and D. Q. H. Wang, “Molecular pathophysiology and physical chemistry of cholesterol gallstones,” Frontiers in Bioscience, vol. 13, no. 2, pp. 401–423, 2008.
[28]  H. Wittenburg and F. Lammert, “Genetic predisposition to gallbladder stones,” Seminars in Liver Disease, vol. 27, no. 1, pp. 109–121, 2007.
[29]  D. Q. H. Wang and N. H. Afdhal, “Gallstone disease,” in Sleisenger and Fordtran's Gastrointestinal and Liver Disease, M. Feldman, L. S. Friedman, and L. J. Brand, Eds., vol. 9, pp. 1089–1120, Elsevier, Philadelphia, Pa, USA, 2010.
[30]  P. Portincasa and G. Calamita, “Water channel proteins in bile formation and flow in health and disease: when immiscible becomes miscible,” Molecular Aspects of Medicine, vol. 33, no. 5-6, pp. 651–664, 2012.
[31]  W. H. Admirand and D. M. Small, “The physicochemical basis of cholesterol gallstone formation in man,” Journal of Clinical Investigation, vol. 47, no. 5, pp. 1043–1052, 1968.
[32]  D. Q. H. Wang and M. C. Carey, “Characterization of crystallization pathways during cholesterol precipitation from human gallbladder biles: identical pathways to corresponding model biles with three predominating sequences,” Journal of Lipid Research, vol. 37, no. 12, pp. 2539–2549, 1996.
[33]  J. J. Clarenbach, M. Reber, D. Lütjohann, K. von Bergmann, and T. Sudhop, “The lipid-lowering effect of ezetimibe in pure vegetarians,” Journal of Lipid Research, vol. 47, no. 12, pp. 2820–2824, 2006.
[34]  K. F. Kozarsky, M. H. Donahee, A. Rigotti, S. N. Iqbal, E. R. Edelman, and M. Krieger, “Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels,” Nature, vol. 387, no. 6631, pp. 414–417, 1997.
[35]  S. J. Robins and J. M. Fasulo, “High density lipoproteins, but not other lipoproteins, provide a vehicle for sterol transport to bile,” Journal of Clinical Investigation, vol. 99, no. 3, pp. 380–384, 1997.
[36]  E. Sehayek, J. G. Ono, S. Shefer et al., “Biliary cholesterol excretion: a novel mechanism that regulates dietary cholesterol absorption,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 17, pp. 10194–10199, 1998.
[37]  J. F. Oram and J. W. Heinecke, “ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease,” Physiological Reviews, vol. 85, no. 4, pp. 1343–1372, 2005.
[38]  Y. A. Kesaniemi and T. A. Miettinen, “Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population,” European Journal of Clinical Investigation, vol. 17, no. 5, pp. 391–395, 1987.
[39]  M. S. Bosner, L. G. Lange, W. F. Stenson, and R. E. Ostlund Jr., “Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry,” Journal of Lipid Research, vol. 40, no. 2, pp. 302–308, 1999.
[40]  S. W. Altmann, H. R. Davis Jr., L. J. Zhu et al., “Niemann-pick C1 like 1 protein is critical for intestinal cholesterol absorption,” Science, vol. 303, no. 5661, pp. 1201–1204, 2004.
[41]  D. Q. H. Wang, “Regulation of intestinal cholesterol absorption,” Annual Review of Physiology, vol. 69, pp. 221–248, 2007.
[42]  D. Q. H. Wang and S. P. Lee, “Physical chemistry of intestinal absorption of biliary cholesterol in mice,” Hepatology, vol. 48, no. 1, pp. 177–185, 2008.
[43]  S. D. Turley and J. M. Dietschy, “The metabolism and excretion of cholesterol by the liver,” in The Liver: Biology and Pathobiology, I. M. Arias, W. B. Iakoby, H. Popper, D. Schachter, and D. A. Shafritz, Eds., pp. 617–641, Raven Press, New York, NY, USA, 1988.
[44]  M. A. Long, E. W. Kaler, and S. P. Lee, “Structural characterization of the micelle-vesicle transition in lecithin-bile salt solutions,” Biophysical Journal, vol. 67, no. 4, pp. 1733–1742, 1994.
[45]  S. H. Quarfordt, B. Oswald, B. Landis, H. S. Xu, S. H. Zhang, and N. Maeda, “In vivo cholesterol kinetics in apolipoprotein E-deficient and control mice,” Journal of Lipid Research, vol. 36, no. 6, pp. 1227–1235, 1995.
[46]  S. J. Robins and H. Brunengraber, “Origin of biliary cholesterol and lecithin in the rat: contribution of new synthesis and preformed hepatic stores,” Journal of Lipid Research, vol. 23, no. 4, pp. 604–608, 1982.
[47]  C. C. Schwartz, M. Berman, and Z. R. Vlahcevic, “Multicompartmental analysis of cholesterol metabolism in man. Characterization of the hepatic bile acid and biliary cholesterol precursor sites,” Journal of Clinical Investigation, vol. 61, no. 2, pp. 408–423, 1978.
[48]  Q. Chen, W. J. Li, Y. Y. Wan, C. D. Yu, and W. G. Li, “Fibroblast growth factor receptor 4 Gly388Arg polymorphism associated with severity of gallstone disease in a Chinese population,” Genetics and Molecular Research, vol. 11, no. 1, pp. 548–555, 2012.
[49]  S. W. Beaven and P. Tontonoz, “Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia,” Annual Review of Medicine, vol. 57, pp. 313–329, 2006.
[50]  D. J. Peet, B. A. Janowski, and D. J. Mangelsdorf, “The LXRs: a new class of oxysterol receptors,” Current Opinion in Genetics and Development, vol. 8, no. 5, pp. 571–575, 1998.
[51]  P. Tontonoz and D. J. Mangelsdorf, “Liver X receptor signaling pathways in cardiovascular disease,” Molecular Endocrinology, vol. 17, no. 6, pp. 985–993, 2003.
[52]  H. Uppal, Y. Zhai, A. Gangopadhyay et al., “Activation of liver X receptor sensitizes mice to gallbladder cholesterol crystallization,” Hepatology, vol. 47, no. 4, pp. 1331–1342, 2008.
[53]  C. J. Tsai, M. F. Leitzmann, W. C. Willett, and E. L. Giovannucci, “Statin use and the risk of cholecystectomy in women,” Gastroenterology, vol. 136, no. 5, pp. 1593–1600, 2009.
[54]  R. Erichsen, T. Fr?slev, T. L. Lash, L. Pedersen, and H. T. S?rensen, “Long-term statin use and the risk of gallstone disease: a population-based case-control study,” The American Journal of Epidemiology, vol. 173, no. 2, pp. 162–170, 2011.
[55]  B. A. Chapman, M. J. Burt, R. J. Chisholm, R. B. Allan, K. H. J. Yeo, and A. G. Ross, “Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor,” Digestive Diseases and Sciences, vol. 43, no. 2, pp. 349–353, 1998.
[56]  D. S. Hanson and W. C. Duane, “Effects of lovastatin and chenodiol on bile acid synthesis, bile lipid composition, and biliary lipid secretion in healthy human subjects,” Journal of Lipid Research, vol. 35, no. 8, pp. 1462–1468, 1994.
[57]  J. W. A. Smit, K. J. van Erpecum, P. Portincasa, W. Renooij, D. W. Erkelens, and G. P. van Berge-Henegouwen, “Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia,” Gut, vol. 37, no. 5, pp. 654–659, 1995.
[58]  J. C. Mitchell, G. M. Logan, B. G. Stone, and W. C. Duane, “Effects of lovastatin on biliary lipid secretion and bile acid metabolism in humans,” Journal of Lipid Research, vol. 32, no. 1, pp. 71–78, 1991.
[59]  J. L. Smith, P. D. Roach, L. N. Wittenberg et al., “Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones,” Journal of Gastroenterology and Hepatology, vol. 15, no. 8, pp. 871–879, 2000.
[60]  H. Vanhanen, Y. A. Kesaniemi, and T. A. Miettinen, “Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, fecal steroids, and cholesterol absorption in man,” Metabolism: Clinical and Experimental, vol. 41, no. 6, pp. 588–595, 1992.
[61]  F. Lammert, D. Q. H. Wang, B. Paigen, and M. C. Carey, “Phenotypic characterization of Lith genes that determine susceptibility to cholesterol cholelithiasis in inbred mice: integrated activities of hepatic lipid regulatory enzymes,” Journal of Lipid Research, vol. 40, no. 11, pp. 2080–2090, 1999.
[62]  S. M. Grundy, A. L. Metzger, and R. D. Adler, “Mechanisms of lithogenic bile formation in American Indian women with cholesterol gallstones,” Journal of Clinical Investigation, vol. 51, no. 12, pp. 3026–3043, 1972.
[63]  P. H. Key, G. G. Bonorris, and J. W. Marks, “Biliary lipid synthesis and secretion in gallstone patients before and during treatment with chenodeoxycholic acid,” Journal of Laboratory and Clinical Medicine, vol. 95, no. 6, pp. 816–826, 1980.
[64]  F. O. Nervi, C. F. Covarrubias, V. D. Valdivieso, B. O. Ronco, A. Solari, and J. Tocornal, “Hepatic cholesterogenesis in Chileans with cholesterol gallstone disease. Evidence for sex differences in the regulation of hepatic cholesterol metabolism,” Gastroenterology, vol. 80, no. 3, pp. 539–545, 1981.
[65]  G. Salen, G. Nicolau, S. Shefer, and E. H. Mosbach, “Hepatic cholesterol metabolism in patients with gallstones,” Gastroenterology, vol. 69, no. 3, pp. 676–684, 1975.
[66]  E. F. Stange and J. M. Dietschy, “Cholesterol absorption and metabolism by the intestinal epithelium,” in Sterols and Bile Acids, H. Danielsson and J. Sjovall, Eds., pp. 121–149, Elsevier, Amsterdam, The Netherlands, 1985.
[67]  H. Y. I. Mok, K. von Bergmann, and S. M. Grundy, “Effects of continuous and intermittent feeding on biliary lipid outputs in man: application for measurements of intestinal absorption of cholesterol and bile acids,” Journal of Lipid Research, vol. 20, no. 3, pp. 389–398, 1979.
[68]  K. K. Buhman, M. Accad, S. Novak et al., “Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice,” Nature Medicine, vol. 6, no. 12, pp. 1341–1347, 2000.
[69]  H. H. Wang and D. Q. H. Wang, “Reduced susceptibility to cholesterol gallstone formation in mice that do not produce apolipoprotein B48 in the intestine,” Hepatology, vol. 42, no. 4, pp. 894–904, 2005.
[70]  L. Amigo, V. Quiones, P. Mardones et al., “Impaired biliary cholesterol secretion and decreased gallstone formation in apolipoprotein E-deficient mice fed a high-cholesterol diet,” Gastroenterology, vol. 118, no. 4, pp. 772–779, 2000.
[71]  L. DenBesten, W. E. Connor, and S. Bell, “The effect of dietary cholesterol on the composition of human bile,” Surgery, vol. 73, no. 2, pp. 266–273, 1973.
[72]  H. Dam, I. Prange, M. K. Jensen, H. E. Kallehauge, and H. J. Fenger, “Studies on human bile—IV. Influence of ingestion of cholesterol in the form of eggs on the composition of bile in healthy subjects,” Zeitschrift für Ern?hrungswissenschaft, vol. 10, no. 3, pp. 178–187, 1971.
[73]  E. Andersen and K. Hellstrom, “The effect of cholesterol feeding on bile acid kinetics and biliary lipids in normolipidemic and hypertriglyceridemic subjects,” Journal of Lipid Research, vol. 20, no. 8, pp. 1020–1027, 1979.
[74]  D. W. T. Lee, C. J. Gilmore, G. Bonorris et al., “Effect of dietary cholesterol on biliary lipids in patients with gallstones and normal subjects,” The American Journal of Clinical Nutrition, vol. 42, no. 3, pp. 414–420, 1985.
[75]  T. Gilat, C. Feldman, and Z. Halpern, “An increased familial frequency of gallstones,” Gastroenterology, vol. 84, no. 2, pp. 242–246, 1983.
[76]  R. E. Sampliner, P. H. Bennett, L. J. Comess, F. A. Rose, and T. A. Burch, “Gallbladder disease in pima indians. Demonstration of high prevalence and early onset by cholecystography,” The New England Journal of Medicine, vol. 283, no. 25, pp. 1358–1364, 1970.
[77]  S. K. Sarin, V. S. Negi, R. Dewan, S. Sasan, and A. Saraya, “High familial prevalence of gallstones in the first-degree relatives of gallstone patients,” Hepatology, vol. 22, no. 1, pp. 138–141, 1995.
[78]  C. S. Stokes, M. Krawczyk, and F. Lammert, “Gallstones: environment, lifestyle and genes,” Digestive Diseases, vol. 29, no. 2, pp. 191–201, 2011.
[79]  H. Wittenburg, “Hereditary liver disease: gallstones,” Best Practice and Research: Clinical Gastroenterology, vol. 24, no. 5, pp. 747–756, 2010.
[80]  D. Katsika, A. Grjibovski, C. Einarsson, F. Lammert, P. Lichtenstein, and H. U. Marschall, “Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs,” Hepatology, vol. 41, no. 5, pp. 1138–1143, 2005.
[81]  D. Katsika, P. Magnusson, M. Krawczyk et al., “Gallstone disease in Swedish twins: risk is associated with ABCG8 D19H genotype,” Journal of Internal Medicine, vol. 268, no. 3, pp. 279–285, 2010.
[82]  M. Acalovschi, A. Ciocan, O. Mostean et al., “Are plasma lipid levels related to ABCG5/ABCG8 polymorphisms? A preliminary study in siblings with gallstones,” European Journal of Internal Medicine, vol. 17, no. 7, pp. 490–494, 2006.
[83]  H. Gylling, M. Hallikainen, J. Pihlajam?ki et al., “Polymorphisms in the ABCG5 and ABCG8 genes associate with cholesterol absorption and insulin sensitivity,” Journal of Lipid Research, vol. 45, no. 9, pp. 1660–1665, 2004.
[84]  S. C. Chuang, E. Hsi, and K. T. Lee, “Mucin genes in gallstone disease,” Clinica Chimica Acta, vol. 413, no. 19-20, pp. 1466–1471, 2012.
[85]  S. C. Chuang, E. Hsi, S. N. Wang, M. L. Yu, K. T. Lee, and S. H. Juo, “Polymorphism at the mucin-like protocadherin gene influences susceptibility to gallstone disease,” Clinica Chimica Acta, vol. 412, no. 23-24, pp. 2089–2093, 2011.
[86]  H. L. Xu, J. R. Cheng, G. Andreotti et al., “Cholesterol metabolism gene polymorphisms and the risk of biliary tract cancers and stones: a population-based case-control study in Shanghai, China,” Carcinogenesis, vol. 32, no. 1, pp. 58–62, 2011.
[87]  L. M. Berends and S. E. Ozanne, “Early determinants of type-2 diabetes,” Best Practice and Research Clinical Endocrinology and Metabolism, vol. 26, no. 5, pp. 569–580, 2012.
[88]  E. R. Gilbert and D. Liu, “Epigenetics: the missing link to understanding beta-cell dysfunction in the pathogenesis of type 2 diabetes,” Epigenetics, vol. 7, no. 8, pp. 841–852, 2012.
[89]  M. S. Martin-Gronert and S. E. Ozanne, “Metabolic programming of insulin action and secretion,” Diabetes, Obesity and Metabolism, vol. 14, supplement 3, pp. 29–39, 2012.
[90]  F. I. Milagro, M. L. Mansego, M. C. De, and J. A. Martinez, “Dietary factors, epigenetic modifications and obesity outcomes: progresses and perspectives,” Molecular Aspects of Medicine, 2012.
[91]  S. Sookoian and C. J. Pirola, “DNA methylation and hepatic insulin resistance and steatosis,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 15, no. 4, pp. 350–356, 2012.
[92]  J. Wang, Z. Wu, D. Li et al., “Nutrition, epigenetics, and metabolic syndrome,” Antioxidants and Redox Signaling, vol. 17, no. 2, pp. 282–301, 2012.
[93]  M. A. Dawson and T. Kouzarides, “Cancer epigenetics: from mechanism to therapy,” Cell, vol. 150, no. 1, pp. 12–27, 2012.
[94]  M. A. Dawson, T. Kouzarides, and B. J. Huntly, “Targeting epigenetic readers in cancer,” The New England Journal of Medicine, vol. 367, no. 7, pp. 647–657, 2012.
[95]  C. Marsit and B. Christensen, “Blood-derived DNA methylation markers of cancer risk,” Advances in Experimental Medicine and Biology, vol. 754, pp. 233–252, 2013.
[96]  S. Udali, P. Guarini, S. Moruzzi, S. W. Choi, and S. Friso, “Cardiovascular epigenetics: from DNA methylation to microRNAs,” Molecular Aspects of Medicine, 2012.
[97]  J. B. Kwok, “Role of epigenetics in Alzheimers and Parkinsons disease,” Epigenomics, vol. 2, no. 5, pp. 671–682, 2010.
[98]  J. A. Piedrahita, “The role of imprinted genes in fetal growth abnormalities,” Birth Defects Research A, vol. 91, no. 8, pp. 682–692, 2011.
[99]  Y. J. Loke, B. Novakovic, M. Ollikainen et al., “The peri/postnatal epigenetic twins study (PETS),” Twin Research and Human Genetics, vol. 16, no. 1, pp. 13–20, 2013.
[100]  F. M. Low, P. D. Gluckman, and M. A. Hanson, “Developmental plasticity and epigenetic mechanisms underpinning metabolic and cardiovascular diseases,” Epigenomics, vol. 3, no. 3, pp. 279–294, 2011.
[101]  R. Cong, Y. Jia, R. Li et al., “Maternal low-protein diet causes epigenetic deregulation of HMGCR and CYP7alpha1 in the liver of weaning piglets,” The Journal of Nutritional Biochemistry, vol. 23, no. 12, pp. 1647–1654, 2012.
[102]  G. Sohi, K. Marchand, A. Revesz, E. Arany, and D. B. Hardy, “Maternal protein restriction elevates cholesterol in adult rat offspring due to repressive changes in histone modifications at the cholesterol 7α-hydroxylase promoter,” Molecular Endocrinology, vol. 25, no. 5, pp. 785–798, 2011.
[103]  T. F. Cheng, S. Choudhuri, and K. Muldoon-Jacobs, “Epigenetic targets of some toxicologically relevant metals: a review of the literature,” Journal of Applied Toxicology, vol. 32, no. 9, pp. 643–653, 2012.
[104]  R. Martinez-Zamudio and H. C. Ha, “Environmental epigenetics in metal exposure,” Epigenetics, vol. 6, no. 7, pp. 820–827, 2011.
[105]  J. F. Reichard and A. Puga, “Effects of arsenic exposure on DNA methylation and epigenetic gene regulation,” Epigenomics, vol. 2, no. 1, pp. 87–104, 2010.
[106]  N. Sadli, M. L. Ackland, M. D. De, A. J. Sinclair, and C. Suphioglu, “Effects of zinc and DHA on the epigenetic regulation of human neuronal cells,” Cellular Physiology and Biochemistry, vol. 29, no. 1-2, pp. 87–98, 2012.
[107]  B. Wang, Y. Li, C. Shao, Y. Tan, and L. Cai, “Cadmium and its epigenetic effects,” Current Medicinal Chemistry, vol. 19, no. 16, pp. 2611–2620, 2012.
[108]  T. Ding, M. McConaha, K. L. Boyd, K. G. Osteen, and K. L. Bruner-Tran, “Developmental dioxin exposure of either parent is associated with an increased risk of preterm birth in adult mice,” Reproductive Toxicology, vol. 31, no. 3, pp. 351–358, 2011.
[109]  R. McKinlay, J. A. Plant, J. N. B. Bell, and N. Voulvoulis, “Calculating human exposure to endocrine disrupting pesticides via agricultural and non-agricultural exposure routes,” Science of the Total Environment, vol. 398, no. 1–3, pp. 1–12, 2008.
[110]  E. Nilsson, G. Larsen, M. Manikkam, C. Guerrero-Bosagna, M. I. Savenkova, and M. K. Skinner, “Environmentally induced epigenetic transgenerational inheritance of ovarian disease,” PloS ONE, vol. 7, no. 5, Article ID e36129, 2012.
[111]  T. Takeda, M. Fujii, J. Taura, Y. Ishii, and H. Yamada, “Dioxin silences gonadotropin expression in perinatal pups by inducing histone deacetylases: a new insight into the mechanism for the imprinting of sexual immaturity by dioxin,” The Journal of Biological Chemistry, vol. 287, pp. 18440–18450, 2012.
[112]  B. Weinhold, “More chemicals show epigenetic effects across generations,” Environmental Health Perspectives, vol. 120, article A228, 2012.
[113]  A. Ferrari, E. Fiorino, M. Giudici et al., “Linking epigenetics to lipid metabolism: focus on histone deacetylases,” Molecular Membrane Biology, vol. 29, no. 7, pp. 257–266, 2012.
[114]  J. C. Chuang and P. A. Jones, “Epigenetics and microRNAs,” Pediatric Research, vol. 61, no. 5, pp. 24R–29R, 2007.
[115]  W. Y. Tang and S. M. Ho, “Epigenetic reprogramming and imprinting in origins of disease,” Reviews in Endocrine and Metabolic Disorders, vol. 8, no. 2, pp. 173–182, 2007.
[116]  J. A. Martinez, P. Cordero, J. Campion, and F. I. Milagro, “Interplay of early-life nutritional programming on obesity, inflammation and epigenetic outcomes,” The Proceedings of the Nutrition Society, vol. 71, no. 2, pp. 276–283, 2012.
[117]  S. Y. Rhee, Y. C. Hwang, J. T. Woo et al., “Blood lead is significantly associated with metabolic syndrome in Korean adults: an analysis based on the Korea national health and nutrition examination survey (KNHANES), 2008,” Cardiovascular Diabetology, vol. 12, no. 1, article 9, 2013.
[118]  S. Unisa, P. Jagannath, V. Dhir, C. Khandelwal, L. Sarangi, and T. K. Roy, “Population-based study to estimate prevalence and determine risk factors of gallbladder diseases in the rural Gangetic basin of North India,” HPB, vol. 13, no. 2, pp. 117–125, 2011.
[119]  V. Ambros, “The functions of animal microRNAs,” Nature, vol. 431, no. 7006, pp. 350–355, 2004.
[120]  D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism, and function,” Cell, vol. 116, no. 2, pp. 281–297, 2004.
[121]  D. P. Bartel, “MicroRNAs: target recognition and regulatory functions,” Cell, vol. 136, no. 2, pp. 215–233, 2009.
[122]  K. J. Moore, K. J. Rayner, Y. Suárez, and C. Fernández-Hernando, “MicroRNAs and cholesterol metabolism,” Trends in Endocrinology and Metabolism, vol. 21, no. 12, pp. 699–706, 2010.
[123]  M. G. Ross and M. H. Beall, “Adult sequelae of intrauterine growth restriction,” Seminars in Perinatology, vol. 32, no. 3, pp. 213–218, 2008.
[124]  B. Lamarche, S. Lemieux, G. R. Dagenais, and J. P. Després, “Visceral obesity and the risk of ischaemic heart disease: insights from the Québec cardiovascular study,” Growth Hormone and IGF Research, vol. 8, pp. 1–8, 1998.
[125]  M. Makishima, A. Y. Okamoto, J. J. Repa et al., “Identification of a nuclear receptor for bite acids,” Science, vol. 284, no. 5418, pp. 1362–1365, 1999.
[126]  D. J. Parks, S. G. Blanchard, R. K. Bledsoe et al., “Bile acids: natural ligands for an orphan nuclear receptor,” Science, vol. 284, no. 5418, pp. 1365–1368, 1999.
[127]  J. J. Repa and D. J. Mangelsdorf, “The liver X receptor gene team: potential new players in atherosclerosis,” Nature Medicine, vol. 8, no. 11, pp. 1243–1248, 2002.
[128]  N. Y. Kalaany and D. J. Mangelsdorf, “LXRs and FXR: the Yin and Yang of cholesterol and fat metabolism,” Annual Review of Physiology, vol. 68, pp. 159–191, 2006.
[129]  J. Lee, S. Seok, P. Yu et al., “Genomic analysis of hepatic farnesoid X receptor binding sites reveals altered binding in obesity and direct gene repression by farnesoid X receptor in mice,” Hepatology, vol. 56, no. 1, pp. 108–117, 2012.
[130]  O. de Bari, B. A. Neuschwander-Tetri, M. Liu, P. Portincasa, and D. Q. Wang, “Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic fatty liver disease,” Journal of Lipids, vol. 2012, Article ID 302847, 16 pages, 2012.

Full-Text

comments powered by Disqus